Company intelligence / Profile preview

ImYoo

Ownership: Private
Development stage: Preclinical

Overview

ImYoo has built a database of self-collected capillary blood immune profiles from over 100 people, with over 2.4M single cells and nuclei processed, enabling identification of over 40 unique immune cell subtypes[5].

Therapeutic areas: GastroenterologyRheumatologyImmunology
Modalities: Single-cell RNA sequencingMulti-omic analysis
Industry: Molecular Diagnostics

Partnerships

YourBio Health (for TAP II blood collection device)[5]Jumpcode Genomics[3]

Beyond the preview

Go deeper on ImYoo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ImYoo.

Explore the full profile